Citations

Clear

4847 citation(s) found for "Tu, Eric".

Effectiveness of Placebo Therapy for Maintaining Masking in a Clinical Trial of Vergence/Accommodative Therapy
Kulp, Marjean Taylor , Mitchell, G. Lynn , Borsting, Eric , Scheiman, Mitchell , Rouse, Michael , Tamkins, Susanna M. , Reuter, Kathleen, Cotter, Susan A. , Mohney, Brian G. , Toole, Andrew J.

Mayo Clinic

Investigative Opthalmology & Visual Science | May 26, 2009 | Volume: 50 | Issue: 6 | Pages: 2560

10.1167/iovs.08-2693 | PMID 19151384 Get It

Human Glucocorticoid Receptor α Gene (NR3C1) Pharmacogenomics: Gene Resequencing and Functional Genomics
Niu, Nifang, Kalari, Krishna R. , Moon, Irene, Pelleymounter, Linda L., Eckloff, Bruce W., Wieben, Eric D. , Schaid, Daniel J. , Wang, Liewei , Manickam, Venkatraman , Kalari, Krishna R

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | May 13, 2009 | Volume: 94 | Issue: 8 | Pages: 3072-3084

10.1210/jc.2008-2109 | PMID 19435830 Get It

Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
Reiman, Eric M. , Chen, Kewei , Bandy, Daniel, Yu, Meixiang , Lee, Wendy , Ayutyanont, Napatkamon , Keppler, Jennifer, Reeder, Stephanie, Alexander, Gene E. , Klunk, William E. , Mathis, Chester A. , Price, Julie C. , Aizenstein, Howard , DeKosky, Steven T. , Caselli, Richard J. , Liu, Xiaofen , Reeder, Stephanie, Langbaum, Jessica B. S.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 3, 2009 | Volume: 106 | Issue: 16 | Pages: 6820-6825

10.1073/pnas.0900345106 | PMID 19346482 Get It

Fibrillar amyloid-beta (Aβ) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Aβ burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Aβ burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) ε4 allele. The 8 ε4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Aβ was significantly associated with APOE ε4 carrier status and ε4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Aβ burden in cognitively normal older people is associated with APOE ε4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Aβ accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Aβ, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Aβ imaging in primary prevention trials.
Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke
Zoppo, Gregory J. del, Levy, David E., Wasiewski, Warren W., Pancioli, Arthur , Demchuk, Andrew M., Trammel, James, Kaste, Markku , Albers, Gregory W. , Ringelstein, Eric B., Demaerschalk, Bart M.

Mayo Clinic

Stroke | March 19, 2009 | Volume: 40 | Issue: 5 | Pages: 1687-1691

10.1161/strokeaha.108.527804 | PMID 19299642 Get It

Background and Purpose— Epidemiological studies have found strong correlations between elevated plasma fibrinogen levels and both ischemic stroke incidence and stroke mortality. Little is known about the influence of fibrinogen levels on functional stroke outcome. Methods— Placebo data from the Stroke Treatment with Ancrod Trial (STAT) and European Stroke Treatment with Ancrod Trial (ESTAT) were analyzed. Fibrinogen levels were determined within 3 hours (STAT) or 6 hours (ESTAT) of stroke onset and at preset intervals throughout 5 days of intravenous infusions. Barthel Index scores at 90 days quantified functional outcomes. The association between initial fibrinogen levels and functional outcomes was evaluated using a multiple logistic regression analysis. Results— Fibrinogen levels increased gradually over the first 24 hours from a pretreatment median value of 340 mg/dL to a 24-hour median value of 376 mg/dL. In a univariate analysis, the proportion of patients with good functional outcome decreased with increasing quartiles of initial fibrinogen levels in both STAT (36.0% to 26.2%) and ESTAT (53.8% to 24.8%). In a multifactorial analysis, the same trend was observed. Patients with initial fibrinogen levels <450 mg/dL had better outcomes in both studies; the difference (42.0% versus 21.6%) was significant in ESTAT ( P =0.0006), even when corrected for age and initial stroke severity. Conclusion— The independent association of higher initial fibrinogen levels with poor outcome needs to be verified using a larger acute stroke dataset. Even in the present small populations, the apparent association of these 2 variables suggests that treatments designed to reduce fibrinogen levels could potentially be important in treating acute ischemic stroke.
Mutations in Regulatory Subunit Type 1A of Cyclic Adenosine 5′-Monophosphate-Dependent Protein Kinase ( PRKAR1A ): Phenotype Analysis in 353 Patients and 80 Different Genotypes
Bertherat, Jérôme , Groussin, Lionel , Grabar, Sophie , Boikos, Sosipatros A. , Cazabat, Laure , Libé, Rossella , René-Corail, Fernande, Stergiopoulos, Sotirios, Bourdeau, Isabelle , Bei, Thalia, Clauser, Éric , Calender, Alain , Kirschner, Lawrence S. , Bertagna, Xavier, Carney, J. Aidan, Stratakis, Constantine A. , Horvath, Anélia , Stratakis, Constantine A

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 17, 2009 | Volume: 94 | Issue: 6 | Pages: 2085-2091

10.1210/jc.2008-2333 | PMID 19293268 Get It

Prolonged Transgene Expression with Lentiviral Vectors in the Aqueous Humor Outflow Pathway of Nonhuman Primates
Barraza, Román, Rasmussen, Carol A. , Loewen, Nils A. , Cameron, J. Douglas, Gabelt, B’Ann T., Teo, Wulin , Kaufman, Paul L., Poeschla, Eric M.

Mayo Clinic

Human Gene Therapy | March 17, 2009 | Volume: 20 | Issue: 3 | Pages: 191-200

10.1089/hum.2008.086 | PMID 19301472 Get It

Methadone Isomers and Their Role in Pain Management
Prommer, Eric

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | March 12, 2009 | Volume: 26 | Issue: 2 | Pages: 149-150

10.1177/1049909109332652 | PMID 19282393 Get It

Family Presence During Resuscitation
Twedell, Diane, Engelhardt, Eric, Twedell, Diane, Engelhardt, Eric

Mayo Clinic

The Journal of Continuing Education in Nursing | March 11, 2009 | Volume: 39 | Issue: 12 | Pages: 530-531

10.3928/00220124-20081201-05 | PMID 19110726 Get It

Family presence during resuscitation is becoming an increasingly well-known and sometimes controversial issue among health care providers. Institutional support in the form of position statement and guideline development can assist in the implementation of a family presence program; however, more research is needed into all areas of the practice. Nurses can play an integral role in a practice that demonstrates exceptional attention to the needs of the family and, ultimately, the patient. J Contin Educ Nurs 2008;39(12):530–531.
Treatment of Urinary Incontinence Due to Incomplete Spinal Cord Injury With Acupuncture and Percutaneous Electrical Nerve Stimulation: Two Cases and Literature Review
Dorsher, Peter T. , Reimer, Ronald, Nottmeier, Eric W.

Mayo Clinic

Medical Acupuncture | February 26, 2009 | Volume: 21 | Issue: 1 | Pages: 21-26

10.1089/acu.2009.0630 Get It

Meta-analysis of Oncogenic Protein Kinase Cι Signaling in Lung Adenocarcinoma
Erdogan, Eda, Klee, Eric W. , Thompson, E. Aubrey , Fields, Alan P.

Mayo Clinic

Clinical Cancer Research | February 18, 2009 | Volume: 15 | Issue: 5 | Pages: 1527-1533

10.1158/1078-0432.ccr-08-2459 | PMID 19223491 Get It

Abstract Purpose: Atypical protein kinase Cι (PKCι) is an oncogene in non–small cell lung cancer (NSCLC). Here, we identify four functional gene targets of PKCι in lung adenocarcinoma (LAC), the most prominent form of NSCLC. Experimental Design: Three independent public domain gene expression data sets were interrogated to identify genes coordinately expressed with PKCι in primary LAC tumors. Results were validated by QPCR in an independent set of primary LAC tumors. RNAi-mediated knockdown of PKCι and the target genes was used to determine whether expression of the identified genes was regulated by PKCι, and whether these target genes play a role in anchorage-independent growth and invasion of LAC cells. Results: Meta-analysis identified seven genes whose expression correlated with PKCι in primary LAC. Subsequent QPCR analysis confirmed coordinate overexpression of four genes (COPB2, ELF3, RFC4, and PLS1) in an independent set of LAC samples. RNAi-mediated knockdown showed that PKCι regulates expression of all four genes in LAC cells, and that the four PKCι target genes play an important role in the anchorage-independent growth and invasion of LAC cells. Meta-analysis of gene expression data sets from lung squamous cell, breast, colon, prostate, and pancreas carcinomas, as well as glioblastoma, revealed that a subset of PKCι target genes, particularly COPB2 and RFC4, correlate with PKCι expression in many tumor types. Conclusion: Meta-analysis of public gene expression data are useful in identifying novel gene targets of oncogenic PKCι signaling. Our data indicate that both common and cell type–specific signaling mechanisms contribute to PKCι-dependent transformation.